Neuroprotective Genes For Retinitis Pigmentosa Treatment and The Foreseeable Future Foundation

Dr. Daniel Kerschensteiner (Washington University - St. Louis, MO)

Dr. Philip Ruzycki (Washington University - St. Louis, MO)

Foreseeable Future Foundation (Franklin, TN)

Dr. Daniel Kerschensteiner, Bernard Becker Professor of Ophthalmology and Visual Sciences, and Dr. Philip Ruzycki, Assistant Professor of Ophthalmology and Visual Sciences, Washington University in St. Louis, discuss how the neuroprotective genes, UFD1 and UXT, were discovered to be tested in gene therapies to treat retinitis pigmentosa.

Then, Griffin Pinkow, CEO and Founder, Foreseeable Future Foundation, explains how the foundation provides programs to empower those who are blind or have low vision through sports and recreation.

 8/30/2026 Podcast (Click Image Below)

GLP-1 Drugs Effect On Ischemic Optic Neuropathy and AI-Assisted Tool To Mitigate African-American Disparities In Eye Care

Dr. Chintan Dave (Rutgers University - New Brunswick, NJ)

Dr. Alvin Liu (Johns Hopkins University - Baltimore, MD)

Dr. Chintan Dave, Associate Professor and Director of Health Outcomes, Policy, and Economics (HOPE), Rutgers University, explains how much the use of GLP-1 drugs affects the risk of developing ischemic optic neuropathy, which involves decreased or blocked blood flow to the optic nerve. 

Dr. Alvin Liu, Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, discusses how an AI-assisted tool can be used to cut down on the disparities in eye care for diabetic African-Americans.

8/16/2026 Podcast (Click Image Below)